PEPTIDE GUIDE

What Is Mod GRF 1-29?

Mod GRF 1-29 is a laboratory-made 29-amino-acid peptide intended to imitate the active part of growth hormone-releasing hormone, the natural signal that prompts the pituitary gland to release growth hormone. It is commonly sold as “CJC-1295 No DAC”, but that name can create the false impression that it shares the clinical evidence of long-acting CJC-1295 DAC.

The intended sequence is usually described as GHRH(1-29) with four amino-acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27. These changes are meant to reduce enzymatic breakdown while preserving activity at the GHRH receptor. Unlike CJC-1295 DAC, it has no albumin-binding Drug Affinity Complex.

The US Food and Drug Administration, normally shortened to FDA, has not approved Mod GRF 1-29 as a medicine. FDA has evaluated several CJC-1295-related substances for possible use in pharmacy compounding, but that regulatory process is not drug approval.

Research statusUnapproved GHRH analogue without direct human clinical evidence
Common market nameCJC-1295 No DAC
Peptide typeModified 29-amino-acid GHRH fragment
Human evidenceNo direct clinical studies located
Last reviewedSeptember 2026
THE SHORT ANSWER

Mod GRF 1-29, commonly called CJC-1295 No DAC, is an unapproved modified fragment of human growth hormone-releasing hormone. Its four substitutions have a scientific basis in older structure, stability and receptor research. However, no direct human clinical trial of the exact marketed Mod GRF 1-29 form was located. Human studies of native GHRH(1-29), partly modified analogues and CJC-1295 DAC can explain the pathway, but they cannot prove the pharmacokinetics, benefits or safety of Mod GRF 1-29. FDA has also documented naming and identity problems across CJC-1295-related substances.

What do GRF, GHRH and 1-29 mean?

Growth hormone-releasing factor, shortened to GRF, is an older name for growth hormone-releasing hormone, shortened to GHRH. The two terms refer to the same natural signalling hormone.

Human GHRH contains 44 amino acids. Amino acids are the small building blocks joined together to make peptides and proteins. Researchers found that the first 29 amino acids contain the region needed to activate the GHRH receptor. GHRH(1-29) therefore means amino acids 1 through 29 of the full hormone.

The word “Mod” means modified. Mod GRF 1-29 is not simply the natural 1-to-29 sequence. Four positions are changed. The common chemical description is [D-Ala2, Gln8, Ala15, Leu27]-GHRH(1-29)-NH2. NH2 shows that the end of the peptide is amidated.

Part of the nameMeaning
ModThe natural fragment has been chemically modified
GRF or GHRHGrowth hormone-releasing factor or hormone
1-29The molecule is based on the first 29 amino acids of the 44-amino-acid hormone
D-Ala2D-alanine replaces ordinary alanine at position 2
Gln8Glutamine replaces asparagine at position 8
Ala15Alanine replaces glycine at position 15
Leu27Leucine replaces methionine at position 27
NH2The C-terminal end is amidated

Why is it called CJC-1295 No DAC?

The name grew out of the structure of CJC-1295 DAC. The original CJC-1295 development compound used a modified GHRH(1-29) backbone and added an albumin-binding Drug Affinity Complex, abbreviated to DAC. The DAC component gave it a multi-day estimated half-life in early human research.

Removing that albumin-binding part leaves a peptide corresponding to the modified 29-amino-acid backbone. The research market commonly calls this “CJC-1295 without DAC” or “CJC-1295 No DAC”. Mod GRF 1-29 is the clearer name because the peer-reviewed CJC-1295 clinical papers studied the DAC compound.

This is not a minor naming issue. Adding or removing an albumin-binding component changes molecular mass, distribution, clearance, duration and potentially safety. The long-acting human CJC-1295 results cannot simply be reassigned to the no-DAC material.

FDA examined CJC-1295 free base and acetate separately from three CJC-1295 DAC forms. It found that identifiers, chemical structures and certificates did not consistently match the names submitted. FDA also found no human clinical safety information for the non-DAC free-base or acetate substances it evaluated.

For this guide, Mod GRF 1-29 means the intended tetrasubstituted 29-amino-acid GHRH analogue without the albumin-binding DAC group. A product label does not prove that a vial contains that exact structure.

How is Mod GRF 1-29 different from CJC-1295 DAC?

The shared element is the modified GHRH(1-29) sequence. The important difference is the albumin-binding extension.

FeatureMod GRF 1-29CJC-1295 DAC
Peptide backboneModified GHRH(1-29)Modified GHRH(1-29)
Four common substitutionsD-Ala2, Gln8, Ala15 and Leu27D-Ala2, Gln8, Ala15 and Leu27
Drug Affinity ComplexAbsentPresent
Albumin bindingNot designed to form the DAC covalent bondDesigned to bind albumin after administration
Direct human pharmacokinetic studyNone located for the exact Mod GRF formSmall studies reported an estimated 5.8-to-8.1-day half-life
Direct clinical benefit evidenceNone locatedNone established; studies mainly measured hormone changes
ApprovalNot approvedNot approved

Some descriptions give Mod GRF 1-29 a precise half-life of about 30 minutes. A precise number was not established in a direct published human pharmacokinetic study of the exact tetrasubstituted marketed peptide located for this review. The reasonable conclusion is that removing the albumin-binding DAC should make exposure much shorter than CJC-1295 DAC. The exact duration in people remains unverified.

How does the normal GHRH system work?

The hypothalamus, a hormone-controlling region of the brain, produces GHRH. It sends GHRH to the pituitary gland through a specialised local blood supply. GHRH activates receptors on somatotrophs, the pituitary cells that make growth hormone.

Growth hormone enters the bloodstream in pulses. The pattern reflects a changing balance between GHRH, which encourages release, and somatostatin, which restrains it. Sleep, age, sex, nutrition, exercise and illness also influence the pattern.

Growth hormone acts directly on some tissues. It also stimulates production of insulin-like growth factor 1, normally shortened to IGF-1, in the liver and other tissues. IGF-1 supports normal growth and tissue maintenance and feeds information back to the brain and pituitary.

Mod GRF 1-29 is intended to activate the GHRH receptor. It is not growth hormone and does not directly supply IGF-1. It depends on a functioning pituitary with growth hormone available for release. FDA notes that complete growth hormone deficiency would not be expected to respond adequately to a GHRH-like secretagogue.

Secretagogue means a substance that prompts a gland to release a substance it already stores. It does not mean that the response is necessarily normal, beneficial or safe.

What is Mod GRF 1-29 made from?

The intended molecule contains 29 amino-acid residues. Most are ordinary L-amino acids, the orientation used in human proteins. D-alanine at position 2 is a mirror-image amino acid. Its different orientation can make the nearby peptide bond harder for some enzymes to cut.

The other three substitutions use familiar amino acids:

  • Glutamine replaces asparagine at position 8.
  • Alanine replaces glycine at position 15.
  • Leucine replaces methionine at position 27.

These changes were selected from decades of GHRH structure-activity research. A structure-activity study changes parts of a molecule and measures how the change affects receptor activity, potency or stability. Finding that a substitution improves one laboratory property does not establish a safe medicine.

The peptide is usually described as C-terminally amidated. The amide is part of the defined chemical structure. The free-base, acetate and trifluoroacetate descriptions concern the associated counterion or chemical form. A counterion balances electrical charge in the solid material and contributes to measured mass and composition.

How is Mod GRF 1-29 synthesised and manufactured?

Mod GRF 1-29 can be made through solid-phase peptide synthesis. A protected amino acid is attached to a solid resin. The remaining protected amino acids are joined one at a time in the reverse direction of the final written sequence. Each cycle removes a temporary protecting group, activates the next amino acid and forms a peptide bond.

The D-alanine raw material must have the correct orientation. The other substitutions must be placed at the correct positions. The final arginine is configured so that the C-terminal end is amidated when the peptide is released from the resin.

After assembly, strong reagents remove the peptide from the resin and clear most protecting groups. The crude mixture can contain incomplete chains, sequences missing one amino acid, oxidised material and products carrying unwanted chemical modifications. Preparative high-performance liquid chromatography, shortened to HPLC, is used to separate the intended product.

Analytical HPLC and mass spectrometry can support identity and purity testing. Mass spectrometry measures mass-to-charge patterns and can help confirm whether the expected 29-amino-acid molecule is present. More detailed sequence analysis may be needed because two peptides can have a similar overall mass while differing at one position.

Manufacture for human administration would require more than a high purity percentage. It would need controlled raw materials, validated impurity limits, residual-solvent testing, water and counterion measurement, stability studies, sterility and endotoxin control. Endotoxins are inflammatory bacterial components that may remain even if no live organism is detected.

FDA has highlighted aggregation, peptide-related impurities and active-ingredient characterisation as safety concerns for CJC-1295-related compounded products. An aggregate is a cluster of peptide molecules. Aggregation can change biological activity and may increase the chance of an immune response.

When was Mod GRF 1-29 first documented?

No single paper marks the birth of the market name Mod GRF 1-29. The molecule sits at the end of a longer chain of research.

Human GHRH was isolated in 1982 from a pancreatic tumour that had caused acromegaly, a condition of excessive growth hormone activity. Researchers soon showed that the 1-to-29 fragment retained growth hormone-releasing activity.

During the 1980s, laboratory and human studies tested substitutions intended to resist rapid breakdown. D-alanine at position 2 was studied directly in normal men. Other work examined changes at positions 8, 15 and 27. By the 1990s, structure-activity programmes had mapped many modified GHRH(1-29) analogues.

ConjuChem's albumin-binding programme later used the tetrasubstituted backbone as part of CJC-1295 DAC. Papers in 2005 and 2006 established the DAC compound's preclinical and early human pharmacology. The name “CJC-1295 without DAC” appeared later in illicit and research-product settings. FDA's 2024 review described a 2010 seized preparation that contained a non-DAC 29-amino-acid sequence and called this the first published reference it located to CJC-1295 without DAC.

PeriodDevelopment
1982The 44-amino-acid human GHRH sequence was isolated and characterised
Early 1980sResearchers established that GHRH(1-29) retained receptor activity
1985Native GHRH(1-29) and a D-Ala2 analogue were compared in five normal men
Late 1980sPartly modified GHRH(1-29) analogues were studied in cells, animals and small human experiments
1990sStructure-activity studies examined stability and receptor effects of substitutions at several positions
2005The modified backbone with an added DAC group was reported as CJC-1295 in rats
2006CJC-1295 DAC entered published studies in healthy adults
2010Researchers identified a non-DAC 29-amino-acid product sold as CJC-1295
2024FDA separately evaluated non-DAC and DAC CJC-1295-related bulk substances
2026No direct completed human clinical programme for the exact Mod GRF 1-29 form was located

How is it expected to work?

The intended mechanism is GHRH-receptor agonism. An agonist is a molecule that activates a receptor. The first amino acids of GHRH make essential contacts with the receptor, while the central and later parts help the peptide hold a useful shape and resist breakdown.

D-alanine at position 2 is intended to slow cleavage by dipeptidyl peptidase enzymes. These enzymes remove or cut amino acids from susceptible peptide ends. A human study of GHRH(1-29) carrying only the D-Ala2 change found that its disappearance half-time increased from about 4.3 minutes for the native fragment to 6.7 minutes for the analogue during constant intravenous infusion. The experiment involved ten normal men.

That finding supports the logic of position 2 modification. It does not establish the half-life of the four-substitution Mod GRF molecule after a different route. Each additional change can alter receptor affinity, enzymatic stability, tissue distribution and clearance.

Alanine at position 15 was explored because it can strengthen the helical shape and receptor binding of GHRH analogues. Changes at positions 8 and 27 were also investigated for stability and potency. Much of this evidence comes from isolated rat pituitary cells or animal experiments rather than from people.

Without DAC, Mod GRF 1-29 is expected to remain a comparatively short signal rather than become an albumin-bound multi-day compound. That expectation is mechanistically reasonable. Direct human concentration-time data are still required before attaching a precise duration to it.

Is there direct human research on Mod GRF 1-29?

No direct clinical trial of the exact tetrasubstituted, non-DAC Mod GRF 1-29 molecule was located in the primary literature or in FDA's detailed review.

This absence matters because several neighbouring evidence streams are often grouped together online:

  1. Human studies of native GHRH(1-29), also known as sermorelin.
  2. Human studies of analogues carrying one or some, but not all, of the Mod GRF substitutions.
  3. Cell and animal studies of modified GHRH sequences.
  4. Human studies of CJC-1295 DAC, which carries the albumin-binding modification.

Each stream can answer a limited question. Native GHRH confirms that the receptor pathway works in people. A D-Ala2 analogue shows how one substitution can change clearance. Laboratory structure-activity work explains why several substitutions were selected. CJC-1295 DAC shows that the backbone plus albumin binding can produce prolonged hormone changes.

None establishes the exact no-DAC product's human half-life, exposure, effective level, clinical benefit or safety. A sound evidence review keeps those boundaries visible.

The Orentra research methodology therefore treats these related studies as supporting context rather than direct clinical evidence for Mod GRF 1-29.

What does the D-Ala2 human study tell us?

A 1985 study gave native GHRH(1-29) and a D-Ala2 GHRH(1-29) analogue to five normal men. The compounds were given as single intravenous boluses at levels ranging from 0.015 to 0.5 micrograms per kilogram.

Intravenous means directly into a vein. A bolus is a single amount given over a short period rather than a continuous infusion. The researchers measured the immediate growth hormone response.

This was relevant early human pharmacology, but it studied only one of the four substitutions in Mod GRF 1-29. It also used an intravenous route and a sample of five. The documented levels identify the historical experiment and are not personal dosing information.

A later study used constant intravenous infusion in ten normal men and compared the disappearance of native GHRH(1-29) with its D-Ala2 analogue. The D-Ala2 version cleared more slowly, but both were still measured on a timescale of minutes rather than days.

Together, these studies show that a position 2 change can retain activity and alter clearance. They do not show how the four-substitution sequence behaves after subcutaneous exposure or repeated use.

What can native GHRH(1-29) studies tell us?

Native GHRH(1-29) has a much larger human research record because it was developed as sermorelin. Studies examined hormone testing and growth in some children with growth hormone deficiency caused by inadequate hypothalamic signalling.

One pharmacokinetic study in healthy participants compared intravenous and intranasal GHRH(1-29). Intranasal means delivered through the nose. Only about 3% to 5% of the intranasal amount reached the bloodstream, showing how route and formulation can change exposure.

A randomised study enrolled 43 prepubertal children with growth hormone deficiency considered to arise from the hypothalamus. It compared two GHRH(1-29) regimens with growth hormone for six months. The higher GHRH group and growth hormone group had similar average growth-promoting effects in that study.

A larger open-label study treated 110 previously untreated children for up to one year with pharmaceutical GHRH(1-29). Open-label means participants and investigators knew what was given. The study reported increased growth velocity in many children.

These studies explain why GHRH(1-29) was once used as a medicine. They do not validate Mod GRF 1-29. The sequence, formulation, manufacturing controls, population and clinical oversight differ. The former FDA approval of Geref, a sermorelin product, does not transfer to a current compounded or research-market peptide.

What do partly modified analogue studies tell us?

Researchers also studied GHRH(1-29) analogues containing selected substitutions. A 1986 paper examined a version with norleucine at position 27 in normal men. Norleucine is a synthetic amino acid used in peptide research and is not the leucine found at position 27 in Mod GRF 1-29. Growth hormone rose quickly after intravenous, subcutaneous and intranasal exposure in that study.

Another study used continuous subcutaneous infusion of the position-27 analogue for eight days in 14 normal men. It found increased growth hormone secretion without clear loss of pituitary responsiveness over that short period. Continuous infusion is not the same exposure pattern as a short-acting bolus, and the molecule was not Mod GRF 1-29.

These studies support two cautious conclusions. A modified 29-amino-acid GHRH fragment can activate the human pathway, and sustained receptor stimulation does not necessarily abolish pulses immediately. They cannot establish the pharmacokinetics or safety of a four-substitution commercial material.

Why do the CJC-1295 DAC trials not answer the question?

CJC-1295 DAC was tested in small randomised controlled studies of healthy adults. One administration produced prolonged increases in growth hormone and IGF-1, and the estimated half-life was 5.8 to 8.1 days.

Those findings depend on the albumin-binding DAC group. Albumin is a common blood protein with a long circulation time. The reactive DAC component forms a strong chemical bond with albumin, protects the peptide from rapid clearance and changes its distribution.

Removing DAC changes the drug. It is not valid to quote the multi-day half-life for Mod GRF 1-29. It is equally invalid to assume that the no-DAC form has the same adverse-event pattern, accumulation or immunogenicity.

The DAC studies can show what prolonged GHRH-receptor activation did in small groups. They cannot fill the missing clinical record for Mod GRF 1-29.

What claimed benefits are supported?

No claimed clinical benefit has been demonstrated directly for Mod GRF 1-29.

ClaimClosest relevant evidenceWhy it does not prove the claim
Raises growth hormoneNative and partly modified GHRH(1-29) analogues raised growth hormone in small human studiesThe exact four-substitution Mod GRF product was not tested directly
Preserves natural pulsesSome GHRH and CJC-1295 DAC research retained pulsatile releaseA pulse pattern does not guarantee normal total exposure or clinical benefit
Builds muscleGrowth hormone and IGF-1 influence tissue metabolismNo controlled Mod GRF trial measured useful muscle gain or strength
Reduces fatGHRH analogues affect the growth hormone axisNo controlled Mod GRF body-composition trial was located
Improves sleepGrowth hormone pulses often occur during sleepTiming within sleep biology is not evidence of better sleep
Speeds recoveryGrowth hormone biology is involved in tissue turnoverNo controlled injury or rehabilitation study was located
Reverses ageingGrowth hormone secretion declines with ageRestoring a youthful hormone marker has not been shown to extend healthy life and may add risk

A plausible mechanism is a reason to conduct a trial, not a substitute for one. Hormone concentrations are biomarkers. A biomarker is a measurable biological sign. It may show that a pathway changed without showing that pain, function, strength, sleep or long-term health improved.

What is known about safety?

There is no direct human safety dataset for the exact Mod GRF 1-29 material. That means the rate of common adverse effects is unknown and uncommon harms cannot be estimated.

Related GHRH compounds provide reasons for monitoring, not precise risk figures. The CJC-1295 DAC studies reported local reactions, headache, diarrhoea, flushing, warmth and temporary low blood pressure. The albumin-binding form is different, so those percentages should not be copied to Mod GRF. They still show that stimulating this pathway is not biologically trivial.

FDA notes that products stimulating the growth hormone and IGF-1 axis may raise concerns similar to approved growth hormone-related medicines. These include glucose intolerance, diabetes, fluid retention, raised pressure inside the skull, effects on thyroid and adrenal function, pancreatitis and the growth of an existing tumour. Evidence is insufficient to say that Mod GRF causes or avoids these outcomes.

Short duration would not make a poorly characterised product safe. Sequence errors, oxidation, aggregates, endotoxin, microbial contamination and incorrect concentration can create risks independent of the intended mechanism. Repeated exposure may also produce a different pattern from one short experiment.

What does FDA say about the non-DAC forms?

Mod GRF 1-29 is not an FDA-approved medicine. FDA's 2024 compounding review considered CJC-1295 free base and CJC-1295 acetate alongside three DAC forms. The agency found no studies establishing whether the nominated non-DAC substances were pharmacologically active as supplied. It also found no human clinical safety information for those specific forms and no evidence of effectiveness for treating growth hormone deficiency.

FDA proposed against adding any of the five CJC-1295-related substances to the section 503A Bulks List. The agency cited unclear physical and chemical characterisation, limited historical-use information, safety concerns and inadequate clinical evidence.

The 503A list concerns ingredients that may be used in traditional pharmacy compounding under defined US conditions. Inclusion would not equal approval, and evaluation does not make a substance an approved medicine. A compounded medicine is not reviewed for safety, effectiveness and manufacturing consistency in the same way as an FDA-approved product.

FDA's current safety page groups CJC-1295-related compounded products with concerns about immune reactions, peptide impurities and active-ingredient identity. The page also notes increased heart rate and systemic vasodilatory reactions associated with CJC-1295, although the form in individual reports may not always be clear.

Is Mod GRF 1-29 prohibited in sport?

Yes. The World Anti-Doping Agency, shortened to WADA, prohibits growth hormone-releasing factors at all times. Its 2026 list names GHRH and analogues including CJC-1295, sermorelin and tesamorelin. Mod GRF 1-29 fits the prohibited GHRH-analogue class even when a particular market name is not separately printed.

The prohibition applies in and out of competition to athletes covered by the World Anti-Doping Code. Analytical laboratories use chromatography and mass spectrometry to detect intact GHRH analogues or characteristic breakdown products.

A 2010 paper is especially relevant to the naming issue. Norwegian police and customs authorities supplied an unknown preparation to a doping laboratory. The researchers identified a 29-amino-acid, C-terminally amidated sequence consistent with non-DAC CJC-1295. The paper showed that a product carrying the name could be analytically identified. It did not establish pharmaceutical quality or clinical safety.

Why does product identity matter so much?

The name on a vial may not identify whether the product contains Mod GRF 1-29, CJC-1295 DAC or another GHRH-related sequence. Even if the intended sequence is listed, a certificate may not establish that the finished vial matches it.

FDA found concrete inconsistencies in identifiers, chemical names, molecular formulae and certificates during its formal evaluation. One submitted sequence matched the non-DAC 29-amino-acid backbone while other identifiers pointed to the DAC form.

Quality questions include:

  • Is the sequence correct at all 29 positions?
  • Is position 2 genuinely D-alanine rather than L-alanine?
  • Is the C-terminal amide present?
  • Is an albumin-binding maleimide group absent?
  • Which counterion and how much residual solvent remain?
  • Are incomplete chains, oxidised forms or aggregates present?
  • Does the finished vial contain the stated quantity?
  • Has sterility and endotoxin control been demonstrated for the finished product?

A purity number alone cannot answer every question. HPLC may show that one main component dominates a sample without proving its full sequence, stereochemistry, sterility or biological suitability.

CompoundReceptor routeStructural featureEvidence and approval
Mod GRF 1-29GHRH receptorFour substitutions in GHRH(1-29), no DACUnapproved; no direct human programme located
CJC-1295 DACGHRH receptorSame modified backbone plus albumin-binding groupUnapproved; small studies in healthy adults
SermorelinGHRH receptorNative-sequence GHRH(1-29) amideFormer approved Geref medicine; current compounded products are not that approval
TesamorelinGHRH receptorModified full-length GHRH analogueUsed in approved EGRIFTA medicines for a specific indication
IpamorelinGhrelin receptorFive-amino-acid growth hormone secretagogueUnapproved; limited human research

Combining a GHRH analogue with a ghrelin-receptor secretagogue is sometimes promoted online. This guide does not provide stacking or combination advice. Direct evidence for a marketed combination's benefit, interaction, exposure and safety would be required. Evidence for each ingredient alone cannot prove the combination.

What would meaningful research need to show?

The first requirement is an exact chemical definition. Researchers would need to confirm sequence, D-alanine orientation, terminal amidation, counterion, impurities and stability. A clinical formulation would need validated sterility and endotoxin controls.

An initial human study would need to measure blood concentrations over time and establish the true half-life. It would also need frequent growth hormone sampling, IGF-1, glucose, insulin, blood pressure, heart rate, fluid-related effects and immune responses. Placebo control and random allocation would reduce bias.

Repeated-exposure research would need to test whether the response changes, whether hormone levels accumulate and whether antibodies appear. A trial in a defined medical condition would then need to measure outcomes that matter to participants, not merely hormone peaks.

Longer follow-up would be necessary for glucose regulation, pituitary changes and tumour-related safety. Separate paediatric development would be essential before any claim involving children. Historical sermorelin experience cannot replace modern testing of a chemically different product.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is Mod GRF 1-29 the same as CJC-1295 No DAC?

Those names are commonly used for the same intended tetrasubstituted GHRH(1-29) peptide without the albumin-binding DAC group. A label still does not prove that a product contains the intended molecule.

Is Mod GRF 1-29 the same as CJC-1295 DAC?

No. CJC-1295 DAC carries an albumin-binding chemical extension that greatly changes its circulation time. Mod GRF 1-29 does not contain that component.

Is Mod GRF 1-29 an approved medicine?

No. It is not FDA approved and has no established approved medical indication.

Is Mod GRF 1-29 growth hormone?

No. It is intended to activate the GHRH receptor and prompt the pituitary to release growth hormone. It does not contain growth hormone itself.

How many amino acids does it contain?

The intended peptide contains 29 amino acids and is based on positions 1 to 29 of the natural 44-amino-acid GHRH hormone.

What are its four substitutions?

The intended substitutions are D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27.

What is its half-life?

No precise half-life has been established in a direct published human pharmacokinetic study of the exact Mod GRF 1-29 form located for this review. It should not be assigned the 5.8-to-8.1-day estimate reported for CJC-1295 DAC.

Has Mod GRF 1-29 been tested in people?

No direct clinical trial of the exact four-substitution no-DAC molecule was located. Related native, partly modified and DAC-containing GHRH compounds have been studied, but their results do not establish Mod GRF 1-29's effects.

Do older sermorelin studies prove that it works?

No. Sermorelin uses the native GHRH(1-29) sequence and was studied as a defined pharmaceutical product. Mod GRF 1-29 has four substitutions and current products do not inherit the former Geref approval.

Does the pathway prove muscle gain or fat loss?

No. Growth hormone and IGF-1 influence metabolism, but no controlled Mod GRF trial has shown increased useful muscle, strength or fat loss.

Are the administration levels in this guide recommendations?

No. They identify historical experiments involving related molecules. They are included to explain the evidence and are not personal dosing or administration advice.

What safety information is available?

Direct safety information for the exact molecule is absent. Related compounds raise concerns involving local reactions, cardiovascular effects, glucose control, fluid balance, immune responses and product quality, but the rate of each risk for Mod GRF is unknown.

Is Mod GRF 1-29 prohibited in sport?

Yes. It is a GHRH analogue within WADA's prohibited growth hormone-releasing factor class and is prohibited at all times for covered athletes.

RESEARCH AND MEDICAL NOTICE

This guide explains the research record and its limits. It does not recommend Mod GRF 1-29, provide a dose, describe administration, propose a cycle or advise combining it with another compound. The exact marketed form lacks a direct human clinical evidence base.

RESEARCH LIBRARY

Sources

Regulatory and anti-doping sourcesFDA
FDA: evaluation of CJC-1295-related bulk drug substancesOpen source →
Regulatory and anti-doping sourcesFDA
FDA: compounded bulk substances that may present significant safety risksOpen source →
Regulatory and anti-doping sourcesFDA
FDA: bulk drug substances used in compounding under section 503AOpen source →
Regulatory and anti-doping sourcesWorld Anti-Doping Agency
World Anti-Doping Agency: 2026 Prohibited ListOpen source →
Human GHRH and analogue researchPubMed
Human study of GHRH(1-29) and a D-Ala2 analogueOpen source →
Human GHRH and analogue researchPubMed
D-Ala2 GHRH(1-29) half-time and clearance in normal menOpen source →
Human GHRH and analogue researchPubMed
Pharmacokinetics of native GHRH(1-29) in healthy participantsOpen source →
Human GHRH and analogue researchPubMed
Nle27 GHRH(1-29) across three administration routes in normal menOpen source →
Human GHRH and analogue researchPubMed
Continuous infusion of a GHRH(1-29) analogue in 14 normal menOpen source →
Human GHRH and analogue researchPubMed
Randomised GHRH(1-29) and growth-hormone study in 43 childrenOpen source →
Human GHRH and analogue researchPubMed
One-year GHRH(1-29) study in 110 childrenOpen source →
Structure, history and analytical researchPubMed
Guillemin and colleagues: isolation of human growth hormone-releasing factorOpen source →
Structure, history and analytical researchPubMed
Rivier and colleagues: characterisation of human GHRHOpen source →
Structure, history and analytical researchPubMed
Synthesis and activity of D-amino-acid GHRH(1-29) analoguesOpen source →
Structure, history and analytical researchPubMed
Human GHRH(1-29) structure-activity researchOpen source →
Structure, history and analytical researchPubMed
Enhanced stability of modified GHRH analogues in cells and animalsOpen source →
Structure, history and analytical researchPubMed
CJC-1295 DAC albumin-binding development paperOpen source →
Structure, history and analytical researchPubMed
CJC-1295 DAC human pharmacology studyOpen source →
Structure, history and analytical researchPubMed
Identification of a non-DAC 29-amino-acid CJC-1295 productOpen source →
Structure, history and analytical researchPubMed
Detection of GHRH analogues in human plasmaOpen source →

Research reviewed through September 2026.